Avalo Therapeutics, Inc.
AVTX· Nasdaq
Released Aug 6, 2026, before the open
10-Q filed Aug 6, 2026, 37 days after period end · 0001534120-26-000049
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Revenue | — | — | $0.00 | $643.00K |
| Net Income | -$36.36M | -$20.77M | $98.46M | -$8.19M |
| EPS Diluted |
Avalo Therapeutics, Inc. · CIK 1534120 · Engraved from SEC EDGAR
| -$0.83 |
| -$1.92 |
| -$14.07 |
| -$140.73 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.